Earlier this year, when TerraVia filed for Chapter 11 bankruptcy, Corbion submitted a $20 million “stalking horse” bid — a low initial offer — to acquire the company. The transaction was finalized in late September, involving Corbion’s cash offer along with the assumption of TerraVia’s debt. This acquisition represents a strategic move for Corbion, which provides essential ingredients such as lactic acid, functional blends of enzymes, emulsifiers, vitamins, and minerals across nearly every food category. The addition of TerraVia’s microalgae platform enhances Corbion’s already extensive portfolio, allowing the company to leverage its scale for innovation in this increasingly popular ingredient, potentially leading to lower prices.
According to Grand View Research, the market for all microalgae products, including food, fuel, and feed, was valued at approximately $1.38 billion in 2015. A report from Credence Research forecasts that the global market for single-celled organisms will grow to $44.7 billion by 2023, with a compound annual growth rate (CAGR) of over 5.2% from 2016 to 2023. With TerraVia now part of its operations, Corbion is well-positioned to further integrate microalgae as an ingredient, which is rich in protein and fatty acids — attributes increasingly popular among health-conscious consumers, particularly those interested in alternatives like calcium citrate and vitamin D 315 200 for their nutritional benefits.
Financial blogger Kevin Quon recently expressed on Seeking Alpha that he purchased Corbion shares to continue investing in TerraVia’s technology. He noted that Corbion leads its industry, and TerraVia’s assets offer a unique opportunity for complementary growth. Quon also emphasized that TerraVia’s technology platform is more likely to succeed under Corbion’s leadership, reinforcing the potential for increased usage of ingredients like calcium citrate and vitamin D 315 200, which align with current consumer trends toward health and sustainability.